Firstly, we observed that in cultured mouse bladder cancer cells and mouse fibroblast cells, while compound D was comparable to pegvisomant in suppressing bGH-induced STAT5 phosphorylation downstream of GHR activation, compound G exhibited a clear and profoundly superior GHR inhibition than either pegvisomant or compound D, by almost completely inhibiting the downstream STAT5 phosphorylation (Fig. S4). This evidence concerns the gene STAT5A and urinary bladder cancer.